After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved a new option for adult patients with tardive dyskinesia.
After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved a new option for adult patients with tardive dyskinesia.
The US Food and Drug Administration has approved a new treatment option for adult patients with complicated urinary tract infections, including pyelonephritis.
The US Food and Drug Administration has approved a new treatment option for adult patients with complicated urinary tract infections, including pyelonephritis.
The US Food and Drug Administration has approved a new treatment option for adult patients with complicated urinary tract infections, including pyelonephritis.
After clinical trials demonstrated its efficacy and safety, a new treatment option for children with Chagas disease has been approved by the US Food and Drug Administration.